TRITON-TIMI 38 Prasugrel Or Clopidogrel In Percutaneous Intevention?
Gordon Tomaselli
Daniel Jones
REFERENCE: Late Breaking Clinical Trials 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
GORDON TOMASELLI, Johns Hopkins University, Baltimore
COMMENT: DANIEL JONES, President, American Heart Association, University of Mississippi, Jackson
A potential new option for patients with acute coronary syndromes receiving coronary intervention has emerged following a report on the comparison of prasugrel, a new anti-platelet agent, with clopidogrel. Elliott Antman from Brigham and Women’s Hospital in Boston gave the American Heart Association his findings and recommendations about when and in which patients prasugrel might be favored. Gordon Tomaselli discussed the findings with Sarah Maxwell.
GORDON TOMASELLI, Johns Hopkins University, Baltimore
COMMENT: DANIEL JONES, President, American Heart Association, University of Mississippi, Jackson
A potential new option for patients with acute coronary syndromes receiving coronary intervention has emerged following a report on the comparison of prasugrel, a new anti-platelet agent, with clopidogrel. Elliott Antman from Brigham and Women’s Hospital in Boston gave the American Heart Association his findings and recommendations about when and in which patients prasugrel might be favored. Gordon Tomaselli discussed the findings with Sarah Maxwell.
